Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 5, 2017
Reporting Period: Event date of April 5, 2017
This filing reports a significant regulatory milestone regarding the Company's product Trokendi XR.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event rather than financial performance data.
Material Changes
Regulatory Approval: The U.S. Food and Drug Administration (FDA) granted final approval to two Supplemental New Drug Applications (sNDAs) for Trokendi XR.
Label Expansion: The approval expands the label to include the prophylaxis of migraine headache in adults and adolescents 12 years and older.
Timeline: Tentative approval for one sNDA was granted in August 2016. Final approval was contingent upon the expiration of pediatric exclusivity for the innovator's drug in the adolescent population, which occurred on March 28, 2017.
Outlook and Management Commentary
The Company issued a press release on April 5, 2017, to announce the FDA approval. The filing incorporates this press release by reference as Exhibit 99.1. No specific financial guidance, risk factors, or contingencies are detailed within the text of this 8-K filing.
Investor Verification Checklist
- Verify the commercial launch timeline for Trokendi XR for migraine prophylaxis following the April 5, 2017 approval.
- Review the full text of the press release (Exhibit 99.1) for specific management commentary on market expectations.
- Confirm the impact of this label expansion on the Company's overall product pipeline and competitive landscape.
- Check subsequent filings for any financial impact or revenue recognition related to this new indication.